SCHEMBL4156966

SCHEMBL4156966

CCCCCC(=O)N(CC[O])Cc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTB4R2 Q9NPC1 4/20 0.54
CNR2 P34972 1/20 0.54
LMNA P02545 2/20 0.53
NPC1 O15118 1/20 0.53
ALOX15 P16050 1/20 0.53
TSHR P16473 1/20 0.53
MAPK1 P28482 1/20 0.53
HSD17B10 Q99714 1/20 0.53
HDAC1 Q13547 2/20 0.52
HDAC6 Q9UBN7 2/20 0.52
HDAC3 O15379 1/20 0.52
HDAC2 Q92769 1/20 0.52
NCOR2 Q9Y618 1/20 0.52
CA12 O43570 4/20 0.52
CA1 P00915 4/20 0.52
CA2 P00918 4/20 0.52
CA4 P22748 2/20 0.52
ALOX5 P09917 3/20 0.50
ALDH1A1 P00352 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4168772 0.99 CNR2 (0.56) LTB4R2CNR2LMNANPC1ALOX15
SCHEMBL4165489 0.99 CNR2 (0.56) LTB4R2CNR2LMNANPC1ALOX15
SCHEMBL4167794 0.99 CNR2 (0.56) LTB4R2CNR2LMNANPC1ALOX15
SCHEMBL4162457 0.95 LTB4R2 (0.59) LTB4R2CNR2LMNANPC1ALOX15
SCHEMBL4170612 0.93 CNR2 (0.56) LTB4R2CNR2LMNANPC1ALOX15
SCHEMBL4163435 0.92 CNR2 (0.58) LTB4R2CNR2LMNANPC1ALOX15
SCHEMBL4161736 0.92 CNR2 (0.58) LTB4R2CNR2LMNANPC1ALOX15
SCHEMBL4155178 0.92 CNR2 (0.58) LTB4R2CNR2LMNANPC1ALOX15
SCHEMBL27357692 0.91 LTB4R2 (0.56) LTB4R2CNR2LMNANPC1ALOX15
SCHEMBL4167652 0.89 TP53 (0.54) LTB4R2CNR2LMNANPC1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088438-A1 NEW TYROSINE DERIVATIVES AS PPARy MODULATORS LABORATORIOS SALVAT, S.A. (ES) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088438-A1 NEW TYROSINE DERIVATIVES AS PPARy MODULATORS PPARG, PPARD, TYRO3 LTB4R2 490/4885CNR2 109/4885LMNA 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.